Engflag

Mybio

Quick links to important sections

Mybio

Mybio_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mybio

Mybio is a pharmabiotic preparation that is clinically recognized as a probiotic agent, defined as a product containing viable, beneficial microorganisms intended to confer a health benefit on the host. Functionally, the drug is also categorized within the general group of Antidiarrheals. Mybio is typically marketed as an over-the-counter (OTC) dietary supplement, providing accessible support for microbial balance without requiring a prescription.

Quick Facts

Property Description
Active ingredient Lactobacillus acidophilus
Form Oral capsule, tablet, powder for suspension
Pharmacological class Probiotic Agent
Common use Restoration of intestinal flora balance
Origin Natural (live microbial culture)

What Type of Preparation is Mybio, and What is its Active Ingredient?

The single active ingredient in Mybio is the live culture of Lactobacillus acidophilus (L. acidophilus), a specific strain of lactic acid bacteria. This component signifies Mybio as a preparation of natural origin, leveraging organisms that are regular inhabitants of the human gastrointestinal tract. The role of Lactobacillus species as effective probiotics for maintaining a healthy gut environment is well-documented. Mybio is distinguished by its primary focus on this particular strain, often formulated into various formats for the oral route of administration, including the oral capsule and chewable tablet, designed for broad patient group acceptance.

What is the General Purpose of Mybio?

The general purpose of Mybio is to restore and maintain the intestinal flora balance by introducing viable L. acidophilus to the gut. This is achieved primarily through the bacteria's ability to produce lactic acid via fermentation. This metabolic process helps to reduce the intestinal pH, creating an environment that is less conducive to the growth of certain potentially harmful bacteria. The key benefit is that Mybio helps the body fortify its own microbial defenses against digestive disturbances. It is typically used to support the gastrointestinal tract during periods when the natural flora balance is temporarily compromised.

What side effects are possible with Mybio?

Possible Side Effects and Safety Information

Safety information for Mybio, which contains the active ingredient Lactobacillus acidophilus, is derived from government-reviewed regulatory documentation and clinical assessments of probiotic preparations. The majority of reported undesirable effects are related to the Gastrointestinal disorders system-organ class and are generally classified as non-serious.

Officially documented adverse reactions may include common occurrences of flatulence (passing gas), bloating, and mild upset stomach. A specific time-related safety pattern notes that increased intestinal flatus may appear at the beginning of therapy but typically subsides with continued use.

Serious adverse reactions are rare and often categorized with an incidence not known, primarily involving severe manifestations of hypersensitivity (allergic reactions). Signs of a severe allergic response may include a rash, hives, swelling (especially of the face or throat), difficulty breathing, or a fast heartbeat.

Special Population Safety Considerations

The most critical safety constraint relates to specific high-risk patient populations. Use is associated with a heightened, rare risk of systemic infection (e.g., bacteremia or sepsis) in immunocompromised individuals (such as those undergoing chemotherapy or with HIV/AIDS) and patients with severe underlying conditions like a central line or short bowel syndrome. Regulatory warnings advise against use in these vulnerable groups due to the risk posed by the live bacterial component.

Furthermore, official documents note the absence of adequate safety studies in pregnant or breastfeeding women, requiring medical oversight for use in these populations. Safety classifications and terminology used in this section are consistent with standards established by global regulatory authorities.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived from official regulatory documents and outlines the recognized risks and required immediate actions in the event of Mybio overdosage.

Documented Overdose Manifestations

Overdosage with Mybio is associated with specific clinical presentations, which may include severe Central Nervous System (CNS) depression, manifesting as profound somnolence or coma. Significant effects on the Cardiovascular System may occur, including hypotension (low blood pressure) and changes in heart rate. Gastrointestinal distress, such as nausea and profuse vomiting, is also documented. In severe cases, the most serious outcomes involve respiratory arrest and refractory hypotension (shock).

Immediate Actions Required

Immediate medical assistance is required for any known or suspected overdose. Patients or caregivers must promptly contact a certified Poison Control Center or seek urgent evaluation at a hospital emergency department, regardless of whether initial symptoms are mild or absent. Official guidance emphasizes the necessity of establishing and maintaining a patent airway and providing ventilatory support if needed.

Overdose Management and Antidote Status

There is no specific pharmacological antidote or reversal agent officially listed for Mybio overdosage. Management is primarily supportive and symptomatic, focused on maintaining vital functions. Supportive care may involve the use of intravenous fluids, vasopressors for persistent hypotension, and potentially the administration of activated charcoal if the ingestion is recent and the patient's airway is protected. Continuous cardiac and respiratory monitoring is typically required.

Therapeutic Uses of Mybio

Therapeutic Uses and Key Benefits of Mybio

Mybio is a supportive probiotic agent commonly used across domains where additional symptomatic support is needed, helping to manage symptoms that interfere with daily comfort. This preparation is relevant in contexts marked by temporary physiological imbalance and is generally applied in situations involving certain distressing symptoms across the digestive and urogenital tracts. As a supportive agent, Mybio may assist the patient during difficult episodes by helping to ease distress and may contribute to easing the overall symptom load.

The product is commonly used across conditions presenting with acute episodes of diarrhea, in patients managing Irritable Bowel Syndrome (IBS), for digestive difficulties related to lactose intolerance, and as supportive relief for symptoms linked to localized microbial imbalance. It is often used during phases when symptoms become more noticeable, particularly when supportive symptom management is appropriate during or after taking antibiotics, where it may play a role in managing symptoms related to antibiotic-associated diarrhea (AAD).

“This supportive role is particularly valued in situations requiring short-term symptomatic assistance, contributing to supporting day-to-day comfort.”

Quick Fact: Symptomatic Support

Therapeutic Focus Symptom Areas of Focus Typical Context
Bowel Support Loose stools, cramping, bloating, gas Acute diarrhea, IBS flare-ups
Symptomatic Support Irritation, discomfort, functional strain Antibiotic use, urogenital imbalance

Eligibility and Restrictions for Use

Mybio (perfluorohexyloctane ophthalmic solution) is primarily indicated for the treatment of the signs and symptoms of dry eye disease (DED). It works to stabilize the tear film and prevent excessive tear evaporation.

Who Can Use Mybio?

  • Patients, generally adults aged 18 and older, who have been diagnosed with dry eye disease, including those with meibomian gland dysfunction.
  • Individuals who do not have a known hypersensitivity or allergy to perfluorohexyloctane or any other component of the eye drops.

Who Should Not Use Mybio?

The medication is contraindicated and should be avoided by:

Patient Group Reason for Caution/Contraindication
Individuals with known hypersensitivity Contraindicated in patients with a history of allergic reaction to perfluorohexyloctane.
Contact lens wearers Lenses must be removed prior to application and for at least 30 minutes after using the drops.
Pediatric patients Safety and effectiveness have not been established in children under the age of 18.
Pregnant or breastfeeding individuals Use during pregnancy and lactation is not fully studied; treatment should only proceed after careful consideration by a healthcare provider regarding the potential risks and benefits.

It is essential to discuss your full medical history and current medications with a healthcare provider to determine if Mybio is appropriate for your condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mybio, a preparation containing the live culture Lactobacillus acidophilus, has an interaction profile primarily focused on factors that affect the viability of its active ingredient, as defined by government regulatory sources.

Documented Interaction Patterns

Category Official Regulatory Statement
Interacting Medicine Class Antibacterial Agents (Antibiotics)
Mechanistic Basis Pharmacodynamic antagonism resulting in the reduction or loss of viability of the live culture.
Timing-Based Rules Mandatory temporal separation of administration is required. Mybio must be taken at least three hours apart from doses of antibacterial agents to preserve its efficacy.
Substance Restrictions Very Hot Foods or Liquids are restricted because high temperature causes physical inactivation of the live microbial culture.
Systemic PK Interactions None documented, as the active ingredient is not systemically absorbed and does not interact with host metabolic enzymes (e.g., CYP) or drug transporters.

The regulatory profile mandates procedural constraints due to the susceptibility of the live culture. The requirement for administering Mybio at least three hours away from antibiotics is an official rule intended to mitigate the documented risk of its destruction. Similarly, the documented restriction against co-ingestion with very hot substances ensures the active ingredient remains intact for its intended use.

Mechanism of Action

The mechanism of Mybio, which utilizes the live culture of Lactobacillus acidophilus, is defined by a multi-layered action that structurally and metabolically influences the gut microenvironment and the host's intestinal lining. This action focuses exclusively on peripheral pathways to influence processes that regulate microbial community composition and epithelial structure.

Competitive Exclusion and Antagonism

This domain addresses the direct microbiological interaction, where L. acidophilus acts as an antagonist. It exerts its effect by securing adhesion sites on the intestinal epithelium and consuming limiting nutrients, thereby suppressing the growth and proliferation of susceptible microorganisms. This initiates a cascade that results in decreased total population density of susceptible microorganisms.

Barrier Modulation and Local pH Control

This mechanistic cluster involves physicochemical and host-cell signaling. The active bacteria produce Lactic Acid via fermentation, which lowers the local pH to a level that is restrictive to many pathogens. Simultaneously, the culture signals to host cells to strengthen epithelial tight junction proteins, enhancing the physical barrier integrity. This combined action supports modulation of localized cytokine signaling and results in decreased movement of luminal substances into the underlying tissue.

Mechanistic Constraints

The biological activity of this mechanism is intrinsically linked to the viability and specific characteristics of the L. acidophilus strain. The entire mechanistic cascade, including the pH shift and barrier modulation, is severely inhibited if the active culture is destroyed, such as by concurrent use of antibiotics active against this type of microorganism.

Dosage and Administration Information

How to Use Mybio: Official Administration Guidelines

Mybio, containing Lactobacillus acidophilus, is administered exclusively via the oral route. It is available in various official forms, including capsules, tablets (conventional and chewable), and powder for suspension.

Administration Scope

Feature Official Usage Principle
Dosing Regimen Highly variable by product, ranging from once daily to multiple times daily (divided doses). Doses are measured in Colony Forming Units (CFUs).
Timing Constraint Must be administered at least 2 hours after any dose of an antibiotic to ensure the viability of the live culture.
Course Duration Use is typically short-term, often continued for several days after an antibiotic regimen is finished. Self-medication for acute diarrhea should not exceed two days without direction.

Procedural and Handling Instructions

Specific handling instructions apply to the different forms of Mybio. Enteric-coated capsules must be swallowed whole and should not be crushed or chewed, a constraint necessary for the preparation to function as intended. Conversely, the contents of powder forms or granules may be mixed with liquids such as milk, fruit juice, or water for easier intake.

For pediatric patients under 3 years of age, the correct use and dosage must always be determined by a physician. If a dose is missed, it should be taken as soon as possible, but if it is almost time for the next scheduled dose, the missed dose must be skipped; official instructions explicitly state that users must not double the dose.

Recent Clinical Evidence

Recent Clinical Evidence

This section describes the studies that have evaluated the investigational compound, Mybio. It is provided for informational purposes only and does not constitute medical advice or a recommendation for treatment.

Phase 1 and 2 Trials: Initial Examination

Early-stage research focused on the pharmacokinetics and basic tolerability of Mybio in healthy volunteers and small groups of patients. These trials primarily documented the initial tolerability of the compound and identified potential adverse events at various dose levels. An analysis of the study data examined the relationship between the administered dose and measured physiological outcomes. Research has explored the effects of the compound in patients with acute symptoms, but no definitive conclusions regarding long-term outcomes can be drawn from these preliminary studies.

Phase 3 Trials: Key Efficacy and Tolerability Data

Phase 3 trials involved a larger, more diverse patient population and evaluated the compound's effect on measured outcomes and its tolerability profile. The primary goal of these pivotal trials was to measure the compound's association with key endpoints, such as changes in symptom severity and patient-reported quality of life over a defined period.

  • Efficacy Endpoints: Studies examined whether the compound was associated with changes in symptom severity and whether it correlated with a lower frequency of disease-related events.
  • Subgroup Analysis: Studies assessed the compound's tolerability profile in various patient groups, including those with certain co-morbidities. This analysis aimed to document how different patient demographics might affect measured outcomes and tolerability.

Ongoing Research and Evidence Gaps

Long-term observational studies are currently underway to assess potential measured outcomes over multiple years. Evidence remains limited on the effects of continued use beyond the primary trial duration. Further research is examining the exact pathway through which the compound interacts with the body's systems to support the observed findings.

Frequently Asked Questions (FAQ)

Common questions about Mybio (FAQ)

Q: Is it normal to feel no different after taking Mybio for the first few days?

The official product information does not specify an exact timeframe for when the intended effects may begin. The onset of action can vary widely among individuals, and the product is generally intended for short-term use. Official guidance typically focuses on safety profiles rather than a fixed timeline for effects.

Q: Can I take over-the-counter (OTC) pain relievers with Mybio?

According to regulatory documents, the active ingredient in the probiotic preparation of Mybio is not systemically absorbed into the bloodstream. Official product information notes that systemic drug-drug interactions are not expected with non-antibiotic medicines, as the active ingredient is not absorbed into the bloodstream.

Q: Are there any lifestyle changes (like diet or activity) that can affect Mybio?

Official documentation highlights a specific interaction with dietary factors. It explicitly restricts taking Mybio with very hot foods or liquids. This is because high temperatures can cause the physical inactivation of the live microbial culture, potentially affecting its intended action.

Q: What does the latest research evidence say about the benefits of Mybio?

Studies and official information indicate that pivotal Phase 3 clinical trials assessed Mybio's association with key measured outcomes. These trials specifically examined changes in symptom severity and whether the compound correlated with a lower frequency of disease-related events over the study period.

Q: Is it true that Mybio is a biologic or biosimilar medicine?

Mybio is officially classified as a probiotic agent and a pharmabiotic preparation. This means it contains viable, beneficial microorganisms. This type of preparation is defined and classified differently by regulatory bodies than traditional synthetic medicines or typical biologic medicines.

Q: How is Mybio classified by regulatory bodies (e.g., controlled substance)?

Regulatory documents classify Mybio as an Antidiarrheal and a Probiotic Agent, and it is often made available as an over-the-counter (OTC) supplement. Official scheduling checks confirm that Mybio is not listed as a controlled substance by regulatory bodies.

Q: How long does Mybio stay in your system after the last dose?

The active ingredient in the probiotic preparation is not systemically absorbed into the bloodstream. Therefore, it does not have a systemic presence like many other drugs. Its action and presence are confined to the gastrointestinal tract, and it is cleared naturally through the body's normal process of elimination.

Q: Why are there different dosage strengths available for Mybio?

Official product information states that different dosage strengths, measured in Colony Forming Units (CFUs), are available. This is done to accommodate the various official formulations, such as capsules, tablets, and powder for suspension, and to align with specific patient requirements.

Q: Is Mybio safe for older adults (seniors)?

For the ophthalmic solution, appropriate studies performed to date have not demonstrated specific geriatric-related problems that would limit its usefulness in the elderly patient population. Official information does not specify different usage instructions for older adults compared to other adult patients, based on the studies conducted to date.

Q: Does taking Mybio affect my ability to drive or operate machinery?

Regulatory documents note that the ophthalmic solution may cause transient blurred vision immediately following application. This temporary effect could potentially affect the ability to drive or operate machinery. Official guidance states that driving or operating machinery should be avoided until vision has cleared completely.

Q: Can Mybio cause fatigue or dizziness?

Regulatory safety profiles for Mybio predominantly document common adverse reactions related to gastrointestinal disorders, such as flatulence and bloating. Dizziness is not listed as a frequent or common side effect, but official information notes it is a potential sign of a rare, severe allergic reaction.

How should Mybio be stored and disposed of?

Storage Conditions for Mybio

Storage of Mybio (Lactobacillus acidophilus) is strictly controlled to maintain the viability of the live culture. The product must be stored in a closed container at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F).

It is essential to keep the product from freezing and avoid excessive heat. The medicine must be protected from moisture and direct light, meaning storage in high-humidity areas, such as a bathroom, is prohibited. The container must be kept tightly closed to preserve integrity. As a safety measure, the product must be kept out of the reach of children.

Disposal Instructions

Any unused or expired Mybio must be properly discarded. Official guidance states that medication should not be flushed down the toilet or poured into a drain unless specifically instructed to do so. Consult with a pharmacist or local waste disposal service for the correct method to dispose of the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mybio found in:

A-Z Index: